Vertex Pharmaceuticals Inc
vrtx.comWhat Do They Do?
Develops and sells medicines for people with cystic fibrosis, sickle cell disease, beta thalassemia and acute pain, while advancing treatments for other serious diseases.
10-K for FY2025, filed Feb 13, 2026We are a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious…View ↗
Our marketed CF medicines, ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), TRIKAFTA/KAFTRIO (elexacaftor/ tezacaftor/ivacaftor and…View ↗
CASGEVY, our ex-vivo, non-viral CRISPR/Cas9 gene-edited cell therapy, is approved in the U.S., the E.U., the U.K., the Kingdom of Saudi…View ↗
JOURNAVX, our selective non-opioid NaV1.8 pain signal inhibitor, is approved in the U.S. for the treatment of people with…View ↗
How Do They Make Money?
Specialty pharmacies, specialty distributors and wholesalers buy medicines for resale, with sales generally paid after delivery. Small-molecule medicines are paid for when delivered; gene-therapy sales are counted when treatment is infused.
10-K for FY2025, filed Feb 13, 2026F-9 scope of Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers at contract inception, we review the…View ↗
We sell our products primarily to a limited number of specialty pharmacy and specialty distributors globally, as well as to certain major…View ↗
Our payment terms, which typically range from 30 to 150 days depending on the product and market, are consistent with prevailing market…View ↗
-
10-K for FY2025, filed Feb 13, 2026
FY2025 revenue by product or service ↗
$12B
-
10-K for FY2025, filed Feb 13, 2026
$12B ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
TRIKAFTA/KAFTRIO
Sold outright
10-K for FY2025, filed Feb 13, 2026 |
86%
FY2022: 86%
|
TRIKAFTA/KAFTRIO, FY2025
$10.3B Sources
|
Sold outright |
|
ALYFTREK
Sold outright
|
7.0% |
ALYFTREK, FY2025
$837.8M Sources
|
Sold outright |
|
Other product revenues
Sold outright
|
6.8%
FY2022: 14%
|
Other product revenues, FY2025
$820.1M Sources
|
Sold outright |
Who Are Their Customers?
Specialty pharmacies and specialty distributors, along with major U.S. wholesalers, buy the medicines for resale. Vertex also sells to retail pharmacies, hospitals and clinics internationally, and in some markets sells CASGEVY directly to authorized treatment centers.
10-K for FY2025, filed Feb 13, 2026We sell our products primarily to a limited number of specialty pharmacy and specialty distributors globally, as well as to certain major…View ↗
Do Revenues Turn Into Profits?
Yes. It kept 33 cents of every revenue dollar as net income in FY2025 and turned 27 cents into free cash flow.
10-K for FY2025, filed Feb 13, 2026
$4.2BView ↗
10-K for FY2025, filed Feb 13, 2026
$4BView ↗
10-K for FY2025, filed Feb 13, 2026
$3.2BView ↗
How Are They Changing?
10-Q for Q2 FY2026, filed Aug 4, 2026
Open tableView ↗
-
Sep 1, 2026
Appoints Jonathan Poole as chief financial officer
He will take over as CFO on January 1, 2027; Charles Wagner will remain executive vice president and chief operating officer.
Sources
8-K, filed Sep 1, 2026
On August 27, 2026, Vertex Pharmaceuticals Incorporated (the “Company”) appointed Jonathan Poole as Executive Vice President and Chief…View ↗
-
Aug 3, 2026
Raises 2026 revenue guidance
The company lifted its full-year revenue outlook to $13.1 billion to $13.2 billion from $12.95 billion to $13.1 billion.
Sources
8-K, filed Aug 3, 2026
Vertex today raised its full year 2026 total revenue guidance to $13.1 billion to $13.2 billion from $12.95 billion to $13.1 billion…View ↗
-
Jul 7, 2026
Agrees to acquire Crinetics Pharmaceuticals
The proposed merger would make Crinetics a wholly owned subsidiary; closing was expected in the third quarter of 2026.
Sources
8-K, filed Jul 7, 2026
On July 6, 2026, Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (“Parent”), Clark Merger Sub, Inc., a Delaware…View ↗
Growing. Revenue grew 58% in 4 years, from $7.6B in FY2021 to $12B in FY2025, about 12% a year.
Expanded marketed disease areas
The older report described approved medicines for cystic fibrosis, while the latest report also describes approved medicines for sickle cell disease, beta thalassemia and acute pain.
10-K for FY2022, filed Feb 10, 2023 10-K for FY2025, filed Feb 13, 2026We are a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious…View ↗
We are a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious…View ↗
Loading...
